Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 5
2004 9
2005 10
2006 12
2007 14
2008 8
2009 12
2010 12
2011 12
2012 16
2013 17
2014 27
2015 14
2016 12
2017 18
2018 13
2019 14
2020 16
2021 12
2022 14
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

260 results

Results by year

Filters applied: . Clear all
Page 1
Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes.
Parker VER, Robertson D, Erazo-Tapia E, Havekes B, Phielix E, de Ligt M, Roumans KHM, Mevenkamp J, Sjoberg F, Schrauwen-Hinderling VB, Johansson E, Chang YT, Esterline R, Smith K, Wilkinson DJ, Hansen L, Johansson L, Ambery P, Jermutus L, Schrauwen P. Parker VER, et al. Among authors: johansson l. Nat Metab. 2023 Dec;5(12):2086-2093. doi: 10.1038/s42255-023-00938-0. Epub 2023 Dec 8. Nat Metab. 2023. PMID: 38066113 Free PMC article. Clinical Trial.
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial.
Noureddin M, Khan S, Portell F, Jorkasky D, Dennis J, Khan O, Johansson L, Johansson E, Sanyal AJ. Noureddin M, et al. Among authors: johansson l. Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1094-1105. doi: 10.1016/S2468-1253(23)00198-X. Epub 2023 Oct 5. Lancet Gastroenterol Hepatol. 2023. PMID: 37806314 Clinical Trial.
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Fernández AP, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S. Ladds MJGW, et al. Among authors: johansson l. Nat Commun. 2023 Aug 18;14(1):5019. doi: 10.1038/s41467-023-40764-2. Nat Commun. 2023. PMID: 37596290 Free PMC article. No abstract available.
260 results